ATG-101 is under clinical development by Antengene and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ATG-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATG-101 overview
ATG-101 is under development for the treatment of hematological, B-Cell Non-Hodgkin Lymphoma, pancreatic cancer, triple-negative breast cancer, metastatic colon adenocarcinoma, glioblastoma multiforme, gastric cancer, head and neck squamous cell carcinoma, cervical cancer and solid tumors. The drug candidate is a bi-specific monoclonal antibody. It acts by targeting tumor necrosis factor receptor superfamily member 9 (4-1BB or CD137) and programmed cell death 1 ligand 1 (PD-L1). It is administered through intravenous route.
Antengene overview
Antengene is a biopharmaceutical company that discovers and develops oncology medicines. The company is investigating ATG-010, a first-in-class SINE compound targeting XPO1 molecule, to treat multiple myeloma and diffuse large B-cell lymphoma; ATG-008, an mTOR kinase inhibitor for the treatment of solid tumors and hematological malignancies; ATG-016 targeting KRAS-mutant solid tumors and nasopharyngeal carcinoma; ATG-017, signal-regulated kinases 1 and 2 (ERK1/2) inhibitor solid tumors, non-Hodgkin lymphoma, acute myeloid leukemia. It is also evaluating drugs against solid tumors, hematology, and oncology indications. The company has additional office in Shaoxing, Zhejiang, China; and operational presence in Hong Kong and the US. Antengene is headquartered in Shanghai, China.
For a complete picture of ATG-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
